More than 20 million people in the U.S. suffer neuropathic pain. At least 25% of those cases are classified as unexplained and considered cryptogenic sensory polyneuropathy (CSPN). There is no information to guide a physician's drug choices to treat CSPN, but a researcher recently led a first-of-its-kind prospective comparative effectiveness study.
from Health & Medicine News -- ScienceDaily https://www.sciencedaily.com/releases/2020/10/201015173129.htm
No comments:
Post a Comment